Teva, Natco launch 2 additional strengths of generic Revlimid

Teva and Natco are introducing additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg and 20 mg.

The companies launched four other strengths of the product in March 2022. With today’s launch, the companies are offering all of the strengths of lenalidomide in the U.S. market.

Teva’s lenalidomide capsules are used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes and  mantle cell lymphoma following specific prior treatment.

[Read more: Teva rolls out generic Nexavar tablets]

“The launch of additional strengths for the generic version of Revlimid in the U.S. enhances access to an important treatment option for patients, and further demonstrates Teva’s commitment to making generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of U.S. generics and biosimilars, at Teva USA.

Revlimid had annual sales of $2.9 billion as of January 2023, according to IQVIA.

[Read more: Teva intros 2 generics]